Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

Shares of Masimo have lost 32.5% in the past year compared with the industry’s 6.6% decline. The S&P 500 has witnessed 14.9% growth in the said time frame. DaVita, sporting a Zacks Rank #1 ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside. The below comparison of the analyst ratings ...

--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release third quarter 2024 financial results for the period ended September 28, 2024, after the market closes on Tuesday, November 5, 2024. The ...

Masimo Corp. ( (MASI) ) has released its Q3 earnings. Here is a breakdown of the information Masimo Corp. presented to its investors. Masimo ...